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Background: 
 
There are limited data on the safety and efficacy of low
molecular weight heparin (LMWH) in elderly patients with ACS.
 
Aim:
 
 To compare LMWH with unfractioned heparin (UFH) in the manage-
ment of acute MI in elderly patients.
 
Methods: 
 
FAST-MI is a nationwide registry carried out over a 1-month
period in 2005, including consecutive patients with AMI admitted to ICUs <
48 hours from symptom onset in 223 participating centers. We assessed the
impact of LMWH on bleeding, the need for blood transfusion and 12-month
survival in elderly patients (75 years of age or older). 
 
Results: 
 
968 patients treated with heparin were included (Mean age 82 ±
5 years; 51% women; 42.5% STEMI). Major bleeding (2.4% vs 6.1%,
P=0.004) and blood transfusions (4.6% vs 9.7%, P=0.002) were significantly
less important with LMWH compared with the UFH, a difference that per-
sisted after multivariate adjustment (OR=0.41, 95% confidence interval: 0.20-
0.83, and OR=0.49, 95% confidence interval: 0.28-0.85, respectively). 
One-year survival and stroke and reinfarction-free survival were also sig-
nificantly higher with LMWH compared with UFH (OR=0.66, 95% confi-
dence interval: 0.50-0.85 and OR=0.71, 95% confidence interval: 0.56-0.91,
respectively). In two cohorts of patients matched on a propensity score for get-
ting LMWH and with similar baseline characteristics, major bleeding, transfu-
sion and one-year mortality were also significantly lower in patients receiving
LMWH.
 
Conclusion: 
 
The present data show that in elderly patients admitted for
AMI, use of LMWH is associated with less bleeding, less need for transfusion,
and higher survival, compared with the use of UFH.
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Title:
 
 Aldosterone receptor blockade at presentation for ST elevation myo-
cardial infarction is associated with a reduction in potentially lethal ventricular
arrhythmia
 
Purpose:
 
 To assess the benefit of aldosterone receptor blockade on admis-
sion for primary PCI for STEMI. 
 
Methods:
 
 806 consecutive patients admitted within 12 hours after onset of
a STEMI for primary PCI were studied.The latest 111 patients were systemat-
ically treated by 200 mg IV potassium canrenonate at presentation, followed
by soludactone 25 mg daily during the hospital stay.The association between
aldosterone receptor blockade and in-hospital death,ischemic events and ven-
tricular arrhythmia was assessed using a logistic model adjusted on age, Killip
class and reperfusion status.Follow-up was completed in 97% and 96% of
patients at 30 days and 6 months.
 
Results: Results are depicted in the table.Baseline characteristics were not
different between the 2 groups (age 63±14 vs 62±15, successful reperfusion
87% vs 90% and Killip class IV 5% in both groups).Aldosterone receptor
blockade was associated with significantly lower rates of ventricular
arrhythmia with an adjusted OR of 0.18 (95%CI 0.07- 0.47) and 0.25 (95%CI
0.11-0.57) for the ventricular tachycardia and ventricular tachycardia or fibril-
lation respectively, and a trend towards lower rates of resuscitated cardiac
arrest and high grade atrioventricular block.Mortality rates at 30 days (6 vs
6.7%) and 6 months (6.8 vs 7%) were comparable between the groups.
Conclusions: Aldosterone receptor blockade at presentation for STEMI is
associated with a marked reduction of the risk of potentially lethal ventricular
arrhythmia. These findings underline the anti-arrhythmic effect of aldosterone
blockade and the need for adequately sized randomized trials to assess the
benefit of such strategy on major cardiovascular events.
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Aims: Acute coronary syndrome (ACS) with normal coronary angiography
is a frequent clinical situation with an uncertain prognosis. Cardiac magnetic
resonance imaging (CMRI) is a powerful tool for differential diagnosis
between myocardial infarction (MI), acute myocarditis and Tako-tsubo cardi-
omyopathy (TTC). However, CMRI can remain uninformative in many
patients who have no detectable coronary lesion. Data are sparse regarding the
prognosis of patients presenting an ACS with normal coronary arteries on
CMRI. 
Methods: Seventy-nine consecutive patients (mean age 53 years, 39.2 %
male) presenting an ACS with tropinin elevation and normal coronary angiog-
raphy were prospectively included. All patients underwent CMRI at 3-Tesla
within 3 weeks of initial presentation. Adverse events were recorded with a
follow-up of 6 months. 
Results: An identifiable basis for ACS was established by CMRI in 69.6%
of patients (27.8% MI, 29.1% acute myocarditis, 12.7% TTC). Only troponin
level was significantly different between patients with normal vs abnormal
CMRI (3.48 ± 4.3 vs 11.86 ± 11.99 mg/L, respectively, p = 0.0028). During
the follow-up, 1 patient in the MI group suffered stroke (1.26%). In the myo-
carditis group, there was 1 episode of congestive heart failure (1.26%) and 7
patients had recurrent chest pain without troponin elevation (8.6%). Two
patients in the TTC group initially presented with cardiogenic shock (2.53%),
but there were no adverse events in this group during follow-up. In the
remaining 30.2 % patients, no clear diagnosis could be identified by CMRI,
and no adverse events occurred during follow-up. 
Conclusion: CMRI is a useful tool for the management of ACS presenting
with normal coronary angiography, as it helps to ascertain diagnosis and to
adapt treatment in a large proportion of cases. Nonetheless, patients with no
anomalies identified by CMRI have an excellent prognosis, without need for
specific treatment. 
 No aldosterone 
blockade 
(n=695)
Aldosterone 
blockade 
(n=111)
p
In-hospital Death 5.3% 6.31% NS
Ressucitated cardiac 
arrest
7.2% 6.4% NS
Death or ressucitated 
cardiac arrest
8.4% 7.3% NS
Recurrent ischemia 5% 3.6% NS
V tach-V Fib 25.6% 7.3% <0.0001
V tach 24.6% 5.45% <0.00001
High grade AV block 5.8% 1.8% 0.08
